...
首页> 外文期刊>Molecular medicine reports >Expression of HMGB1 in septic serum induces vascular endothelial hyperpermeability
【24h】

Expression of HMGB1 in septic serum induces vascular endothelial hyperpermeability

机译:脓毒症血清中HMGB1的表达诱导血管内皮通透性增高

获取原文
获取原文并翻译 | 示例

摘要

The aim of the present study was to investigate the effects of high mobility group protein B1 (HMGB1), which is expressed in the serum of patients with sepsis, on vascular endothelial permeability. Sera from patients with sepsis were used to treat endothelial cells (ECs), and the effect on endothelial permeability was evaluated using immunofluorescence. The morphologies of endothelial cytoskeletal actin and vascular endothelial (VE)-cadherin were assessed using laser scanning confocal microscopy. The protein expression levels of HMGB1, B-cell lymphoma 2 (BCL-2) and BCL-2-associated X protein (BAX) were detected using western blotting. EC apoptosis was measured using flow cytometry. The results demonstrated that HMGB1 was significantly expressed in the serum 24 h following the onset of sepsis, and the expression levels peaked at 48 h, which were sustained until 96 h post-onset. Compared with the control group, treatment of the ECs with 20% septic serum in vitro significantly increased endothelial monolayer permeability (P<0.01), markedly induced transcellular filamentous (F)-actin rearrangement with stress fiber formation, and resulted in the localization of VE-cadherin fragmentations at the cell borders with increased gaps between ECs. Furthermore, flow cytometry showed that the apoptotic rate of ECs was significantly increased following treatment with septic serum. In addition, the expression levels of BAX were significantly increased, whereas the expression levels of BCL-2 were significantly decreased. Pretreatment with an HMGBI inhibitor (ethyl pyruvate; 5 mu M) 24 h prior to treatment with the septic serum attenuated the effects of septic serum treatment. Together, these findings suggested that treatment of ECs with sera from patients with sepsis may induce the loss of vascular endothelial monolayer integrity, elicit the formation of endothelial F-actin stress fibers and initiate VE-cadherin redistribution, which may be attributed to high levels of HMGB1 in the serum. This mechanism also appears to involve changes in the activation of BAX and BCL-2, resulting in EC apoptosis.
机译:本研究的目的是研究脓毒症患者血清中表达的高迁移率族蛋白B1(HMGB1)对血管内皮通透性的影响。脓毒症患者的血清用于治疗内皮细胞(EC),并使用免疫荧光评估其对内皮通透性的影响。使用激光扫描共聚焦显微镜评估了内皮细胞骨架肌动蛋白和血管内皮(钙)钙粘蛋白的形态。使用蛋白质印迹法检测HMGB1,B细胞淋巴瘤2(BCL-2)和BCL-2相关X蛋白(BAX)的蛋白表达水平。使用流式细胞仪测量EC凋亡。结果表明,脓毒症发作后24 h血清中HMGB1明显表达,其表达水平在48 h达到峰值,并持续至发病后96 h。与对照组相比,体外用20%的化脓性血清治疗ECs显着增加内皮单层通透性(P <0.01),明显诱导跨细胞丝状(F)-肌动蛋白重排,并形成应力纤维,并导致VE定位-钙黏着蛋白碎片在细胞边界与EC之间的间隙增加。此外,流式细胞仪显示,败血性血清处理后,ECs的凋亡率显着增加。另外,BAX的表达水平显着增加,而BCL-2的表达水平显着降低。在使用化脓性血清治疗之前24小时,使用HMGBI抑制剂(丙酮酸乙酯; 5μM)进行预处理可减弱化脓性血清治疗的效果。总之,这些发现表明败血症患者的血清对EC的治疗可能会导致血管内皮单层完整性的丧失,引起内皮F-肌动蛋白应激纤维的形成并引发VE-钙粘蛋白的重新分布,这可能归因于高水平的内皮素。血清中的HMGB1。此机制似乎还涉及BAX和BCL-2激活的变化,从而导致EC凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号